diphenylamine has been researched along with Neurofibromatosis 1 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Bobyn, JD; Deo, N; Little, DG; Schindeler, A | 1 |
| Allen, JC; Blakeley, J; Cutter, G; Dombi, E; Edwards, L; Emoto, C; Fisher, MJ; Fukuda, T; Goldman, S; Korf, B; Packer, R; Plotkin, SR; Ratner, N; Robinson, CT; Robison, NJ; Schorry, E; Tonsgard, JH; Vinks, AA; Weiss, BD; Widemann, BC; Wolters, PL | 1 |
| Little, DG; Mikulec, K; Peacock, L; Schindeler, A; Summers, MA; Vasiljevski, ER | 1 |
| Carpenter, EC; Cheng, T; Deo, N; El-Hoss, J; Little, DG; Mikulec, K; Schindeler, A; Sullivan, K | 1 |
| Cripe, TP; Dombi, E; Dunn, RS; Janhofer, D; Jones, DR; Jousma, E; Kim, MO; Masters, AR; Ratner, N; Rizvi, TA; Wu, J | 1 |
| Chapuis, N; Hivelin, M; Hubas, A; Lantieri, L; Laurendeau, I; Nusbaum, P; Parfait, B; Pasmant, E; Poulain, L; Varin, J; Vidaud, M; Wolkenstein, P | 1 |
| Burga, RA; Fernandes, R; Li, C; Sweeney, EE; Zhu, Y | 1 |
| Akutagawa, J; Braun, BS; Chang, T; Kogan, S; Krisman, K; Lauchle, JO; Shannon, K; Theobald, EH; Xu, J | 1 |
| Aronow, BJ; Brundage, ME; Cripe, TP; Dombi, E; Eaves, D; Giovannini, M; Hardiman Dudley, A; Jessen, WJ; Jousma, E; Kim, MO; Miller, SJ; Niwa-Kawakita, M; Page, GP; Ratner, N; Rizvi, TA; Sabo, J; Widemann, B; Wu, J | 1 |
2 trial(s) available for diphenylamine and Neurofibromatosis 1
| Article | Year |
|---|---|
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Topics: Adolescent; Adult; Benzamides; Diphenylamine; Female; Humans; Magnetic Resonance Imaging; Male; Mitogen-Activated Protein Kinase Kinases; Neurofibroma, Plexiform; Neurofibromatosis 1; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; United States; Young Adult | 2021 |
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Topics: Animals; Benzamides; Child; Child, Preschool; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Mice; Mice, Mutant Strains; Mitogen-Activated Protein Kinase Kinases; Neoplasm Transplantation; Neurofibromatosis 1; Oncogene Protein p21(ras); Peripheral Nervous System Neoplasms; raf Kinases; Transcriptome; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
7 other study(ies) available for diphenylamine and Neurofibromatosis 1
| Article | Year |
|---|---|
Modulation of spine fusion with BMP-2, MEK inhibitor (PD0325901), and zoledronic acid in a murine model of NF1 double inactivation.
Topics: Animals; Benzamides; Diphenylamine; Disease Models, Animal; Mice; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Zoledronic Acid | 2021 |
Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific Nf1 knockout mouse.
Topics: Animals; Animals, Newborn; Benzamides; Diphenylamine; Extremities; Female; Homeodomain Proteins; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Muscular Diseases; MyoD Protein; Neurofibromatosis 1; Neurofibromin 1; ras Proteins; Signal Transduction | 2018 |
A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
Topics: Animals; Benzamides; Bone Morphogenetic Protein 2; Diphenylamine; Disease Models, Animal; Drug Therapy, Combination; Female; Mice; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Osteogenesis; Pseudarthrosis; Recombinant Proteins; Transforming Growth Factor beta | 2014 |
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.
Topics: Animals; Antineoplastic Agents; Benzamides; Diphenylamine; Disease Models, Animal; Enzyme Inhibitors; Immunohistochemistry; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Microscopy, Electron; Neurofibromatosis 1 | 2015 |
Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Nerve Sheath Neoplasms; Neurofibroma, Plexiform; Neurofibromatosis 1; Neurofibromin 1; Nuclear Proteins; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Schwann Cells; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors | 2016 |
Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Topics: Animals; Benzamides; Cell Line, Tumor; Diphenylamine; Disease Models, Animal; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Ferrocyanides; Hyperthermia, Induced; Infrared Rays; Laser Therapy; MAP Kinase Kinase Kinases; Mice; Nanoparticles; Neoplasm Proteins; Neurilemmoma; Neurofibromatosis 1; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Surface Plasmon Resonance | 2016 |
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Topics: Animals; Benzamides; Cell Differentiation; Cell Proliferation; Child; Child, Preschool; Diphenylamine; Disease Models, Animal; Erythropoiesis; Hematopoiesis, Extramedullary; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Juvenile; Mice; Mice, Mutant Strains; Mitogen-Activated Protein Kinase Kinases; Neurofibromatosis 1; Neurofibromin 1 | 2013 |